fosmidomycin
Fosmidomycin is an antibiotic that was originally isolated from culture broths of bacteria of the genus Streptomyces. It specifically inhibits DXP reductoisomerase, a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. It is a structural analogue of 2-C-methyl-D-erythrose 4-phosphate. It inhibits the E. coli enzyme with a KI value of 38 nM (4), MTB at 80 nM, and the Francisella enzyme at 99 nM. Several mutations in the E. coli DXP reductoisomerase were found to confer resistance to fosmidomycin. — Wikipedia
Clinical trial activity
7 trials · 11 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2002 (NCT00217451)
Timeline
Indications
Mechanism of action
ispC inhibitor
1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplastic inhibitor
IspD has also been proposed as a target (PMID: 21438569)
Chemistry & pharmacology
SMILES
O=CN(O)CCCP(=O)(O)O- Mol. weight
- 183.1 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFosmidomycin ↗
- ChEMBLCHEMBL203125 ↗
Also known as
- (3-(formylhydroxyamino)propyl)phosphonic acid, monosodium salt
- 3-(n-formyl-n-hydroxy)aminopropylphosphonic acid
- fosfidomycin
- fosmidomycin
- fosmidomycin
- fosmidomycin
- fosmidomycin
- fosmidomycin
- fosmidomycin monoammonium salt
- fosmidomycin monopotassium salt
- fosmidomycin monosodium salt
- fosmidomycin sodium
- fosmidomycin sodium salt
- fr-31564
- phosphonic acid, (3-(formylhydroxyamino)propyl)-, monosodium salt
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02198807 | Phase 2 | Mar 1, 2014 | Centre de Recherche Médicale de Lambaréné, Jomaa Pharma GmbH |
| NCT01361269 | Phase 2 | Jun 1, 2011 | Albert Schweitzer Hospital, Government of Mozambique, Zentopharm GmbH |
| NCT01464138 | Phase 2 | Sep 1, 2010 | Centre de Recerca en Salut Internacional de Barcelona, Spain., Fundació ACE, Jomaa Pharma GmbH, University of Barcelona |
| NCT01002183 | Phase 2 | Oct 26, 2009 | Jomaa Pharma GmbH, Mahidol University, Thammasat University |
| NCT01464125 | Phase 2 | Nov 1, 2008 | Jomaa Pharma GmbH, Mahidol University, Thammasat University |
| NCT00214643 | Phase 3 | Jun 1, 2005 | Albert Schweitzer Hospital |
| NCT00217451 | Phase 2 | Jun 1, 2002 | Albert Schweitzer Hospital, Kenya Medical Research Institute |
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jomaa Pharma GmbH | For profit | 4 | 4 | 1 | 2008 |
| Albert Schweitzer Hospital | Academic/Hospital | 3 | 2 | 2 | 2002 |
| Mahidol University | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Thammasat University | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Centre de Recerca en Salut Internacional de Barcelona, Spain. | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Centre de Recherche Médicale de Lambaréné | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Fundació ACE | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Government of Mozambique | Government | 1 | 0 | 1 | 2011 |
| Kenya Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Barcelona | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Zentopharm GmbH | For profit | 1 | 1 | 1 | 2011 |